Glox Therapeutics, a Glasgow, Scotland, UK-based developer of precision antibiotic therapies based on naturally occurring bacteriocins, raised £4.3M in seed funding.
The round was led by Boehringer Ingelheim Venture Fund and Scottish Enterprise.
The company intends to use the funds to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria, to establish laboratories in Oxford and Glasgow, and expand its team to accelerate its bacteriocin development program.
Founded in February 2023 by Prof Daniel Walker from the University of Glasgow (now at the University of Strathclyde) and Prof Colin Kleanthous, Fellow of the Academy of Medical Sciences (FMedSci), from the University of Oxford, and led by CEO Dr James Clark, Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens that have already developed AMR, including Pseudomonas aeruginosa and Klebsiella pneumoniae. Bacteriocins, which are naturally produced by bacteria, possess antimicrobial properties against strains of the same or related species. Leveraging bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics. It will focus on selectively eradicating target pathogens while preserving the patient’s microbiomes, ensuring a more balanced and effective treatment strategy with reduced side-effects.
FinSMEs
14/11/2023